Structure-Based Discovery of the SARS-CoV-2 Main Protease Noncovalent Inhibitors from Traditional Chinese Medicine-Reference-Cited by-同舟云学术

Structure-Based Discovery of the SARS-CoV-2 Main Protease Noncovalent Inhibitors from Traditional Chinese Medicine

Published:2024-02-12 Issue:4 Volume:64 Page:1319-1330
ISSN:1549-9596
Container-title:Journal of Chemical Information and Modeling
language:en
Short-container-title:J. Chem. Inf. Model.

Author:

Jin Xiaojie¹²³^ORCID,Zhang Min¹,Fu Beibei⁴,Li Mi¹,Yang Jingyi⁵,Zhang Zhiming⁶,Li Chenghao⁷^ORCID,Zhang Huijuan¹,Wu Haibo⁴,Xue Weiwei⁵^ORCID,Liu Yongqi²³

Affiliation:

1. College of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, China

2. Gansu University Key Laboratory for Molecular Medicine and Chinese Medicine Prevention and Treatment of Major Diseases, Gansu University of Chinese Medicine, Lanzhou 730000, China

3. Key Laboratory of Dunhuang Medicine, Ministry of Education, Gansu University of Chinese Medicine, Lanzhou 730000, China

4. School of Life Sciences, Chongqing University, Chongqing 401331, China

5. School of Pharmaceutical Sciences and Innovative Drug Research Centre, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing 401331, China

6. Gansu Provincial Hospital of TCM, Lanzhou 730000, China

7. Medical College, Yangzhou University, Yangzhou 225000, China

Funder

State Administration of Traditional Chinese Medicine of the People's Republic of China

Science and Technology Department of Gansu Province

National Natural Science Foundation of China

Gansu Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jcim.3c01327

Reference52 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. W.H.O. (WHO) World Health Organization. Novel Coronavirus (COVID-19) Situation (accessed Jan 23, 2020).

3. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (accessed May 05, 2023).

4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

5. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the dual role of (+)-catechin as primary antioxidant and inhibitor of viral proteases;Computers in Biology and Medicine;2024-09

2. Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro);ACS Omega;2024-08-02

3. Consensus Pharmacophore Strategy For Identifying Novel SARS-Cov-2 M^pro Inhibitors from Large Chemical Libraries;Journal of Chemical Information and Modeling;2024-03-12